Daiichi Sankyo has started legal action against Seattle Genetics. The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201. In 2008, Seattle Genetics granted Daiichi a license to use its cytotoxin and linker technology in an ADC against a single antigen. The agreement ended in 2015, but Daiichi retained an interest in ADCs, going on to take the HER2-targeting DS-8201-also known as [fam-] trastuzumab deruxtecan-deep enough into the clinic to land a $1.35 billion upfront payment from AstraZeneca. Seattle Genetics thinks it is the rightful owner of ADC technology used in DS-8201 and other Daiichi candidates. Daiichi disagrees. Learn More